171 completed, 43 unknown, 15 withdrawn, 13 terminated. 91 Phase 2, 57 Phase 3, 52 Phase 4, 49 Phase 1, 23 Not applicable.
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 1054 | 2025-04-16 | 2026-10-30 |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema BAT5906 injection, Lucentis - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Bio-Thera Solutions | 406 | 2024-10-09 | 2026-04-07 |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 984 | 2024-08-07 | 2026-11-10 |
| A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Ranibizumab 10mg/ml Injection, Lucentis - Diabetic Macular Edema, Diabetic Retinopathy | Phase 3 | Completed | Incepta Pharmaceuticals Ltd | 70 | 2024-03-30 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | Hoffmann-La Roche | 280 | 2024-03-06 | 2026-07-31 |
| Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Ultra-wide Fluorescein Angiography - Retinal Vein Occlusion, Macular Edema | Unknown | Renmin Hospital of Wuhan University | 60 | 2023-10-09 | 2023-10-18 | |
| Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide - Exudative Age Related Macular Degeneration | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2023-03-30 | 2024-03-22 | |
| A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss 601 1.25mg, ranibizumab 0.5mg - Branch Retinal Vein Occlusion | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 351 | 2022-12-27 | 2025-12-18 |
| Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) Bevacizumab, Ranibizumab Ophthalmic - Wet Age-related Macular Degeneration | Phase 3 | Completed | Parc de Salut Mar | 172 | 2022-11-18 | 2026-11-10 |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration BAT5906 injection, Lucentis - Neovascular (Wet) Age-related Macular Degeneration | Phase 3 | Completed | Bio-Thera Solutions | 488 | 2022-07-07 | 2025-12-08 |
| TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration TAB014 Monoclonal Antibody Injection, Ranibizumab Injection [Lucentis] - Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | BioDlink Biopharm Co., Ltd. | 488 | 2022-06-28 | 2025-01-07 |
| Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity Lucentis - Retinopathy of Prematurity | Completed | Novartis Pharmaceuticals | 69 | 2022-06-22 | 2025-07-04 | |
| A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 394 | 2021-12-31 | 2026-05-11 |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD Standard of Care, Ranibizumab - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Enrolling by invitation | AbbVie | 116 | 2021-12-20 | 2026-08-05 |
| A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 187 | 2021-12-17 | 2025-10-16 |
| Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema Intravitreal ranibizumab, Intravitreal bevacizumab - Diabetic Macular Edema, Macular Ischemia | Phase 4 | Terminated | Cairo University | 5 | 2021-11-26 | 2023-02-16 |
| Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation Ranibizumab Injection [Lucentis], Inner limiting membrane stripping, Dexamethasone intravitreal implant - Diabetic Retinopathy | Phase 3 | Unknown | Affiliated Hospital of Nantong University | 60 | 2021-11-15 | 2023-08-01 |
| Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis - Age Related Macular Degeneration | Phase 3 | Completed | Shanghai Henlius Biotech | 407 | 2021-11-01 | 2025-03-24 |
| A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD MW02, Lucentis - Wet Age-related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 433 | 2021-05-07 | 2022-03-28 |
| 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) 601 1.25mg, Ranibizuman 0.5 mg - Branch Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-28 | 2025-06-27 |
Showing 20 of 248. Sign in to see all of them.
Macular Degeneration (73) · Macular Edema (39) · Retinal Vein Occlusion (30) · Choroidal Neovascularization (23) · Diabetic Retinopathy (18) · Diabetes Mellitus (11) · Vision Disorders (11) · Edema (9) · Polypoidal Choroidal Vasculopathy (9) · Retinal Diseases (9) · Wet Macular Degeneration (8) · Retinal Detachment (5) · Retinopathy of Prematurity (5) · Glaucoma (4) · Glaucoma, Neovascular (4)
Novartis Pharmaceuticals (17) · Genentech, Inc. (8) · Hoffmann-La Roche (5) · Johns Hopkins University (5) · California Retina Consultants (4) · David M. Brown, M.D. (4) · Novartis (4) · University of Sao Paulo (4) · Moorfields Eye Hospital NHS Foundation Trust (3) · Ophthotech Corporation (3) · Southeast Retina Center, Georgia (3) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3) · The New York Eye Cancer Center (3) · University Health Network, Toronto (3) · University of California, San Diego (3)
United States (110) · China (27) · Germany (20) · Canada (17) · South Korea (15) · United Kingdom (15) · Spain (12) · Austria (9) · Australia (8) · Israel (8) · Italy (8) · Poland (8) · Switzerland (8) · Brazil (7) · France (7)
Charles C Wykoff, PhD, MD (2) · Charles Miller, MD PhD (2) · David M Brown, MD (2) · Dennis M. Marcus, M.D. (2) · Diana V Do, MD (2) · Hendrik PN Scholl, MD, MA (2) · Jason Ehrlich, M.D., Ph.D. (2) · Neil M. Bressler, MD (2) · Paul T Finger, MD (2) · Reinier O Schlingemann, MD, PhD (2) · Robert L Avery, MD (2) · Rodrigo Jorge, MD, PhD (2)
PMID 32374423, PMID 34934034, PMID 20417925, PMID 22965590, PMID 23415775, PMID 23699977, PMID 23706949, PMID 23745581, PMID 24768239, PMID 25148789, PMID 26050541, PMID 26452713, PMID 26584450, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30419298, PMID 30957581, PMID 31047350, PMID 31047503, PMID 31668888, PMID 32844399, PMID 36774994, PMID 37585454, PMID 39680390, PMID 12750101, PMID 15564755, PMID 16483659, PMID 16523231, PMID 16581423, PMID 16787141, PMID 16935211, PMID 17021318, PMID 17021319, PMID 17367957, PMID 17804919, PMID 18214740, PMID 19584650, PMID 20142553, PMID 20163368, PMID 20332654, PMID 20572497, PMID 20827138, PMID 20856107, PMID 20877651, PMID 20885313, PMID 21051706, PMID 21232078, PMID 21278146, PMID 21334595
2009 (2), 2014 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1), U10EY014231 (1), U10EY017823 (1), U10EY018817 (1), U10EY024527 (1)